ACEi/ARB Use in CKD: Clear Indications and Stage 5 Guidance
ACE inhibitors and ARBs are strongly indicated in CKD stages G1-G4 with albuminuria (particularly A2-A3), should be continued even when eGFR falls below 30 ml/min/1.73 m², but may need dose reduction or discontinuation in stage 5 CKD (eGFR <15) when uremic symptoms develop, uncontrolled hyperkalemia persists, or symptomatic hypotension occurs 1.
Primary Indications for ACEi/ARB in CKD
The 2024 KDIGO guidelines provide the most authoritative framework:
Strong Indications (Grade 1B-1A recommendations):
- CKD stages G1-G4 with severely increased albuminuria (A3) - both with and without diabetes 1
- CKD stages G1-G4 with moderately-to-severely increased albuminuria (A2-A3) in diabetic patients 1
Moderate Indications (Grade 2C recommendation):
- CKD stages G1-G4 with moderately increased albuminuria (A2) without diabetes 1
Additional Indications:
- Hypertension in CKD - particularly when combined with albuminuria 2
- Heart failure with reduced ejection fraction - even without significant albuminuria 1
- Normal to mildly increased albuminuria (A1) - for specific cardiovascular indications like hypertension or heart failure 1
Critical Implementation Points
Dosing strategy: Use the highest approved tolerated dose, as trial benefits were achieved at these doses 1. This is not a "start low, go slow" situation when the indication is clear.
Monitoring protocol: Check BP, serum creatinine, and potassium within 2-4 weeks of initiation or dose increase 1. This tight monitoring window is essential for safety.
Acceptable creatinine rise: Continue therapy unless creatinine rises >30% within 4 weeks of initiation or dose increase 1. A modest rise is expected and acceptable.
When ACEi/ARB Are NOT Beneficial or Should Be Avoided
Absolute Contraindications:
- Combination therapy with ACEi + ARB + direct renin inhibitor - increases adverse events without additional benefit 2
- Pregnancy - teratogenic effects (general medical knowledge)
Situations Requiring Dose Reduction or Discontinuation:
According to KDIGO 2024, consider reducing dose or stopping in these specific scenarios 1:
- Symptomatic hypotension - not just low numbers, but actual symptoms
- Uncontrolled hyperkalemia despite medical management - after attempting potassium-lowering strategies
- Stage 5 CKD (eGFR <15) with uremic symptoms - to reduce uremic burden while treating kidney failure
Important caveat: Hyperkalemia alone should NOT automatically trigger discontinuation. The guidelines explicitly state that hyperkalemia can often be managed with potassium-lowering measures rather than stopping the RASi 1. This includes dietary modification, diuretics, potassium binders, or newer agents.
Stage 5 CKD (eGFR <15): The Nuanced Answer
The evidence supports continuation of ACEi/ARB even in advanced CKD, including when eGFR falls below 30 ml/min/1.73 m² 1. The 2024 KDIGO guidelines explicitly state: "Continue ACEi or ARB in people with CKD even when the eGFR falls below 30 ml/min per 1.73 m²" 1.
For Stage 5 CKD specifically:
- Default position: Continue therapy if already established and tolerated
- Consider discontinuation only when:
- Uremic symptoms develop that may be reduced by stopping RASi 1
- Symptomatic hypotension occurs
- Hyperkalemia becomes unmanageable despite aggressive treatment
Recent evidence from the STOP-ACEi trial (referenced in 3) showed that discontinuing RASi in advanced CKD did not slow eGFR decline or reduce mortality, while continuation showed a numerical trend toward lower ESKD rates. This supports the guideline recommendation to continue therapy.
Practical Algorithm for Stage 5 CKD:
- If patient is stable on ACEi/ARB: Continue therapy
- Monitor closely: Potassium, creatinine, BP, uremic symptoms
- If hyperkalemia develops: Implement potassium-lowering strategies first (dietary restriction, diuretics, potassium binders)
- If symptomatic hypotension: Consider dose reduction before complete discontinuation
- If uremic symptoms worsen: Consider dose reduction or discontinuation as part of conservative kidney management
- If starting dialysis (KRT): Reassess need, but continuation is reasonable if tolerated
Common Pitfalls to Avoid
Pitfall #1: Stopping ACEi/ARB prematurely when creatinine rises <30% - this modest rise is expected and represents hemodynamic changes, not kidney injury 1.
Pitfall #2: Discontinuing for hyperkalemia without attempting management strategies - potassium binders, dietary modification, and diuretics should be tried first 1.
Pitfall #3: Using submaximal doses - the renoprotective and cardiovascular benefits were demonstrated at target doses in clinical trials 1.
Pitfall #4: Avoiding initiation in stage 4 CKD - the guidelines support continuation even below eGFR 30, so starting in stage 4 is appropriate with proper monitoring 1.
Pitfall #5: Combining ACEi with ARB - this dual blockade increases adverse events without additional benefit and is explicitly not recommended 2.
The Bottom Line on Stage 5
ACEi/ARB remain indicated in stage 5 CKD unless specific complications arise 1. The threshold for discontinuation is high: unmanageable hyperkalemia despite treatment, symptomatic hypotension, or worsening uremic symptoms where stopping may provide relief. The default should be continuation with close monitoring, not automatic discontinuation based on eGFR alone.